Vico

Leiden, Netherlands Founded: 2019 • Age: 7 yrs
RNA modulating therapies for genetic neurological diseases are developed.

About Vico

Vico is a Healthcare company based in Leiden (Netherlands) founded in 2019 by Judith Van Deutekom and Gail Mandel. RNA modulating therapies for genetic neurological diseases are developed. Vico has raised $103.3 million across 3 funding rounds from investors including EQT, Eurazeo and Idinvest Partners. Vico offers products and services including VO659 and ASO Platform. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is VICO Therapeutics B.V.

Company details

Vico was founded in 2019 in Leiden, Netherlands, within the biotechnology sector. Antisense oligonucleotide therapies are designed using the VICOMER platform to target RNA in genetic neurological disorders. Conditions addressed include Rett syndrome, Alzheimers disease, Huntingtons disease, and others. The lead program, VO659, is advanced for polyglutamine-related diseases such as spinocerebellar ataxia types 3 and 1, along with Huntingtons disease. Operations focus on therapeutic development for unmet needs in neurology.

  • Headquarters Leiden, Netherlands
  • Founders Judith Van Deutekom, Gail Mandel
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website vicotx.com
  • Social LinkedIn X
  • Legal Name Vico Therapeutics B.V.
Key Metrics
  • Total Equity Funding
    $103.3M (USD)

    in 3 rounds

  • Latest Funding Round
    $12.3M (USD), Series B

    Jun 2024

  • Investors
    EQT

    & 10 more

Products & Services of Vico

Vico offers a comprehensive portfolio of products and services, including VO659 and ASO Platform.

VO659
Antisense Oligonucleotide Therapy

Targets CAG repeat expansion to reduce mutant proteins in neurological diseases.

ASO Platform
Therapeutic Development

Enables precision targeting of genetic mutations for rare disorders.

Funding Insights of Vico

Vico has successfully raised a total of $103.3M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $12.3 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $103.3M
  • Total Rounds 3
  • Last Round Series B — $12.3M
  • First Round $31M

    (Jul 2020)

  • Investors Count 11

All 3 funding rounds of Vico with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2024$12.3MSeries B–Kurma Partners, Ackermans & van Haaren
Jan 2024$60MSeries B–Ackermans & van Haaren, Droia Ventures
Jul 2020$31MSeries A–Life Sciences Partners, Kurma Partners
Valuation history

11 investors in total: 11 institutional.

Investors in Vico

Vico has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include EQT, Eurazeo and Idinvest Partners.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Seroba Lifesciences is focused on life sciences venture capital investments.
serobavc.comDublin, Ireland
Biotech startups are funded through venture capital in life sciences.
2009kurmapartners.comParis, France
Droia Ventures is focused on investing in drug development companies.
droiaventures.comLuxembourg, Luxembourg
EQT is recognized as a global investment organization focused on value creation.
1994eqtgroup.comStockholm, Sweden
Private equity and debt investments are managed across multiple sectors.
1969eurazeo.comParis, France
US focused venture capital firm
polarispartners.comBoston, United States
Venture capital is invested in innovative drug development companies.
pureosbio.comPfäffikon, Switzerland
Private equity investments in life sciences businesses are managed.
1998lspvc.comAmsterdam, Netherlands
Pontifax Venture Capital is focused on life sciences investments.
pontifax.comHerzeliya, Israel
Equity investments are provided to low and middle market companies.
1997idinvest.comParis, France
Premium access

Investor details for Vico

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Vico

31 people are tracked at Vico (10 in leadership, 8 in board & advisors, 13 in team).

NameRoleGroup
Judith Van Deutekom
Co-Founder & Managing DirectorLeadership
Gail Mandel
Co-FounderLeadership
Micah Mackison
CEOLeadership
Jasper Renz
Sr. Director Regulatory AffairsLeadership
Nicole Datson
Chief Scientific Officer & Site HeadLeadership
Rima Shyamnani
Director Of FinanceLeadership
Piotr Putaj
Director Oligonucleotide ChemistryLeadership
Scott Schobel
Chief Medical OfficerLeadership
Paul Koevoets
Director Analytical ChemistryLeadership
Ruurd Verheul
Associate Director R&dLeadership
Felice Verduyn
Board MemberBoard & advisors
Josh Mandel-Brehm
Co-Founder & Board MemberBoard & advisors
Klaus Breiner
Board MemberBoard & advisors
Amy Schulman
Board MemberBoard & advisors
Martijn Kleijwegt
Board MemberBoard & advisors
Luc Dochez
Founder & Board MemberBoard & advisors
Remi Droller
Board MemberBoard & advisors
Anders Hinsby
Independent Board MemberBoard & advisors
Bas Rottgering
ScientistTeam
Rani van den Eijnde
Scientist Molecular BiologyTeam

11 more people are available in the full profile.

Premium access

Complete people profiles for Vico

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Vico

3 dated milestones of Vico across 5 years, from founding to its latest funding, stage changes and deals.

  1. Founded Vico is founded.
  2. Funding First funding round of $31.0M.
  3. Funding Latest funding round, Series B, of $12.3M.

Web traffic of Vico

The website of Vico (vicotx.com) receives about 2.5K visits a month.

  • Monthly visits
    2.5K

    ▲ 30% vs previous month

Similar websites

Websites whose visitors overlap most with Vico. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
interpulse.nl
100%
#8,540,819View details
bataviabiosciences.com
99%
6.8K#3,268,559View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Vico

Premium access

Complete news archive for Vico

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vico

Vico was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Vico is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.

Vico is a funded company, having raised a total of $103.3M across 3 funding rounds to date. The company's 1st funding round was a Series A of $31M, raised on Jul 2020.

Vico was founded in 2019 in Leiden, Netherlands, within the biotechnology sector. Antisense oligonucleotide therapies are designed using the VICOMER platform to target RNA in genetic neurological disorders. Conditions addressed include Rett syndrome, Alzheimers disease, Huntingtons disease, and others. The lead program, VO659, is advanced for polyglutamine-related diseases such as spinocerebellar ataxia types 3 and 1, along with Huntingtons disease. Operations focus on therapeutic development for unmet needs in neurology.

Vico offers VO659 and ASO Platform.

Vico has 11 investors. Key investors include EQT, Eurazeo, Idinvest Partners, Kurma Partners, and Ackermans & van Haaren.

Vico operates through Vico Therapeutics B.V..

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available